Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

NCT02609386 is registered in ClinicalTrials.gov with Brooklyn ImmunoTherapeutics, LLC as lead sponsor.

NCT NCT02609386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02609386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Lead sponsor
Brooklyn ImmunoTherapeutics, LLC
Phase
Phase 2
Overall status
Completed
Start date
January 11, 2016
Completion date
February 28, 2022
Enrollment
105 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the oral cavity